Antibodies to low-density lipoproteins modified by malonic dialdehyde: contents in blood and role in atherogenesis

In this work, we determined the content of antibodies to low-density lipoproteins modified by malondialdehyde, the concentration of circulating immune complexes cholesterol and oxidized low-density lipoproteins in the blood of healthy individuals and patients with various manifestations of atherosclerosis. In addition, the effect of antibodies to low-density lipoproteins modified with malondialdehyde on the interaction of such lipoproteins with macrophages was studied. 253 persons were examined: healthy individuals (59 people), patients with preclinical atherosclerosis (25 people) and patients with coronary artery disease (169 people). It was found that the concentration of circulating immune complexes cholesterol in plasma was increased in patients with coronary artery disease compared with healthy individuals and patients with preclinical atherosclerosis, while oxidized low-density lipoproteins content did not differ between patients groups. At the same time, a positive correlation oxidized low-density lipoproteins plasma concentration with circulating immune complexes cholesterol content was found in patients with atherosclerosis. The plasma level of IgG antibodies to malondialdehyde-modified lipoproteins was significantly reduced in patients with coronary artery disease compared with healthy people and patients with preclinical atherosclerosis. While the level of IgM antibodies to malondialdehyde low-density lipoproteins practically did not change in patients with atherosclerosis independently of disease severity. It was shown that specific antibodies vastly reduced malondialdehyde low density lipoproteins cytotoxicity and ability to induce cholesterol esters accumulation in macrophages derived from human peripheral blood mononuclear cells. Thus, the data obtained indicate that anti-lipoprotein antibodies may have a protective effect by preventing cell death and reducing the accumulation of cholesterol esters in macrophages when they interact with modified low-density lipoproteins, i.e. prevent the foam cells formation.

1. Denisenko A.D. Autoimmune lipoprotein-antibody complexes and their role in atherogenesis. Meditsinskiy akademicheskiy zhurnal = Medical Academic Journal, 2007, Vol. 7, no. 1, pp. 38-44. (In Russ.)

2. Larionova E.E., Denisenko A.D. The influence of modified low density lipoproteins and of high density lipoproteins on macrophage apoptosis. Uchenye zapiski SPbGMU im. akad. I.P. Pavlova = Scientific Notes of the Pavlov University, 2012, Vol. 19, no. 2, pp. 16-19. (In Russ.)

3. Pigarevsky P.V., Archipova O.Yu., Denisenko A.D. Detection of modified lipoproteins in atherosclerotic lesions of human aorta. Meditsinskaya immunologiya = Medical Immunology (Russia), 2006, Vol. 8, no. 5-6, pp. 637-644. (In Russ.).

4. Amaki T., Suzuki T., Nakamura F., Hayashi D., Imai Y., Morita H., Fukino K., Nojiri T., Kitano S., Hibi N., Yamazaki T., Nagai R. Circulating malondialdehyde modified LDL is a biochemical risk marker for coronary artery disease. Heart, 2004, Vol. 90, no. 10, pp. 1211-1213.

5. Arnhold J., Wiegel D., Richter O., Hammerschmidt S., Arnold K., Krumbiegel M. Modification of low density lipoproteins by sodium hypochlorite. Biomed. Biochim. Acta, 1991, Vol. 50, no. 8, pp. 967-973.

6. Asciutto G., Wigren M., Fredrikson G.N., Mattisson I.Y., Grönberg C., Alm R., Björkbacka H., Dias N.V., Edsfeldt A., Gonçalves I., Nilsson J. Apolipoprotein B-100 Antibody Interaction With Atherosclerotic Plaque Inflammation and Repair Processes. Stroke, 2016, Vol. 47, no. 4, pp. 1140-1143.

7. Belik I.V., Ivantsova A.A., Mamedova Z.E., Denisenko A.D. Antibodies against modified low-density lipoproteins and their complexes in blood of patients with various manifestations of atherosclerosis. Biochem. Moscow Suppl. Ser. B, 2016, Vol. 10, no. 4, pp. 346-350.

8. Berg V.J., Haskard D.O., Fedorowski A., Hartley A., Kardys I., Caga-Anan M., Akkerhuis K.M., Oemrawsingh R.M., van Geuns R.J., de Jaegere P., van Mieghem N., Regar E., Ligthart J.M.R., Umans V.A.W.M., Serruys P.W., Melander O., Boersma E., Khamis R.Y. IgM anti-malondialdehyde low density lipoprotein antibody levels indicate coronary heart disease and necrotic core characteristics in the Nordic Diltiazem (NORDIL) study and the Integrated Imaging and Biomarker Study 3 (IBIS-3). EBioMedicine, 2018, Vol. 36, pp. 63-72.

9. Björkbacka H., Alm R., Persson M., Hedblad B., Nilsson J., Fredrikson G.N. Low levels of apolipoprotein B-100 autoantibodies are associated with increased risk of coronary events. Arterioscler. Thromb. Vasc Biol., 2016, Vol. 36, no. 4, pp. 765-771.

10. Brown M.S., Goldstein J.L. Receptor-mediated endocytosis: Insights from the lipoprotein receptor system, Proc. Natl Acad. Sci. USA, 1979, Vol. 76, no. 7, pp. 3330-3337.

11. Chyu K.Y., Zhao X., Reyes O.S., Babbidge S.M., Dimayuga P.C., Yano J., Cercek B., Fredrikson G.N., Nilsson J., Shah P.K. Immunization using an Apo B-100 related epitope reduces atherosclerosis and plaque inflammation in hypercholesterolemic apo E (−/−) mice. Biochem. Biophys. Res. Commun., 2005, Vol. 338, no. 4, pp. 1982-1989.

12. Denisenko A.D., Makovejchuk E.G., Vinogradov A.G., Kuznetzov A.S., Klimov A.N. Autoantibodies against oxidized low density lipoproteins and lipoprotein-antibody autoimmune complexes in human atherosclerosis. Eur. J. Lab. Med., 1996, Vol. 4, no. 1, pp. 85-90.

13. Fields R. The rapid determination of amino groups with TNBS. Methods Enzymol., 1972, Vol. 25, pp. 464-468.

14. Fogelman A.M., Shechter I., Seager J., Hokom M., Child J.S., Edwards P.A. Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc. Natl Acad. Sci. USA, 1980, Vol. 77, no. 4, pp. 2214-2218.

15. Gonen B., Cole T., Hahm K. S. The interaction of carbamylated low-density lipoprotein with cultured cells. Studies with human fibroblasts, rat peritoneal macrophages and human monocyte-derived macrophages. Biochim. Biophys. Acta, 1983, Vol. 754, no. 2, pp. 201-207.

16. Gruzdeva O., Uchasova E., Dyleva Y., Belik E., Karetnikova V., Shilov A., Barbarash O. Multivessel coronary artery disease, free fatty acids, oxidized LDL and its antibody in myocardial infarction. Lipids Health Dis., 2014, no. 13, 111. doi: 10.1186/1476-511X-13-111.

17. Havel R.J., Eder H.A., Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest., 1955, Vol. 34, no. 9, pp. 1345-1353.

18. Holvoet P., Mertens A., Verhamme P., Bogaerts K., Beyens G., Verhaeghe R., Collen D., Muls E., van de Werf F. Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol., 2001, Vol. 21, no. 5, pp. 844-848.

19. Huang Y., Jaffa A., Koskinen S., Takei A., Lopes-Virella M.F. Oxidized LDL-Containing Immune Complexes Induce Fc Gamma Receptor I Mediated Mitogen-Activated Protein Kinase Activation in THP-1 Macrophages. Arterioscler. Thromb. Vasc. Biol., 1999, Vol. 19, no. 7, pp. 1600-1607.

20. Khamis R.Y., Hughes A.D., Caga-Anan M., Chang C.L., Boyle J.J., Kojima C., Welsh P., Sattar N., Johns M., Sever P., Mayet J., Haskard D.O. High SerumImmunoglobulin G and M Levels Predict Freedom From Adverse Cardiovascular Events in Hypertension: A Nested Case-Control Substudy of the Anglo-Scandinavian Cardiac Outcomes Trial. EBioMedicine, 2016, Vol. 9, pp. 372-380.

21. Lehrer-Graiwer J., Singh P., Abdelbaky A., Vucic E., Korsgren M., Baruch A., Fredrickson J., van Bruggen N., Tang M.T., Frendeus B., Rudd J.H.F, Hsieh F., Ballantyne C.M., Ghoshhajra B., Rosenson R.S., Koren M., Roth E.M., Duprez D.A., Fayad Z.A., Tawakol A.A. FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: a phase II study of safety, tolerability, and anti-inflammatory activity. JACC Cardiovasc. Imaging, 2015, Vol. 8, no. 4, pp. 493-494.

22. Markwell M.A., Haas S.M., Bieber L.L., Tolbert N.E. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal. Biochem., 1978, Vol. 87, no. 1, pp. 206-210.

23. Martos-Folgado I., Del Monte-Monge A., Lorenzo C., Busse C.E., Delgado P., Mur S.M., Cobos-Figueroa L., Escolà-Gil J.C., Martín-Ventura J.L., Wardemann H., Ramiro A.R. MDA-LDL vaccination induces athero-protective germinal-center-derived antibody responses. Cell Rep., 2022, Vol. 41, no. 2, 111468. doi: 10.1016/j.celrep.2022.111468.

24. Meeuwsen J.A.L, van Duijvenvoorde A., Gohar A., Kozma M.O., van de Weg S.M., Gijsberts C.M., Haitjema S., Björkbacka H., Fredrikson G.N., de Borst G.J., den Ruijter H.M., Pasterkamp G., Binder C.J., Hoefer I.E., de Jager S.C.A. High levels of (un)switched memory b cells are associated with better outcome in patients with advanced atherosclerotic disease. J. Am. Heart Assoc., 2017, Vol. 6, no. 9, e005747. doi: 10.1161/JAHA.117.005747.

25. Oksjoki R., Kovanen P.T., Lindstedt K.A., Jansson B., Pentikäinen M.O. OxLDL-IgG Immune Complexes Induce Survival of Human Monocytes. Arterioscler. Thromb. Vasc. Biol., 2005, Vol. 26, no. 3, pp. 576-583.

26. Orekhov A.N., Tertov V.V., Kabakov A.E., Adamova I.Yu., Pokrovsky S.N., Smirnov V.N. Autoantibodies against modified low density lipoprotein. Nonlipid factor of blood plasma that stimulates foam cell formation. Arterioscler. Thromb., 1991, Vol. 11, no. 2, pp. 316-326.

27. Palinski W.S., Ylä-Herttuala S., Rosenfeld M.E, Butler S.W., Socher S.A., Parthasarathy S., Curtiss L.K., Witztum J.L. Antisera and monoclonal antibodies specific for epitopes generated during the oxidative modification of low-density lipoprotein. Arteriosclerosis, 1990, Vol. 10, no. 3, pp. 325-335.

28. Palinski W., Miller E., Witzum J.L. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc. Natl Acad. Sci. USA, 1995, no. 92, pp. 821-825.

29. Ravandi A., Boekholdt S.M., Mallat Z., Talmud P.J., Kastelein J.J., Wareham N.J., Miller E.R., Benessiano J., Tedgui A., Witztum J.L., Khaw K.T., Tsimikas S. Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPICNorfolk Study. J. Lipid Res., 2011, Vol. 52, no. 10, pp. 1829-1836.

30. Rusiñol A.E., Thewke D., Liu J., Freeman N., Panini S.R., Sinensky M.S. AKT/protein kinase B regulation of BCL family members during oxysterol-induced apoptosis. J. Biol Chem., 2004, Vol. 279, no. 2, pp. 1392-1399.

31. Salomon R.G., Kaur K., Podrez E. HNE-derived 2-pentylpyrroles are generated during oxidation of LDL, are more prevalent in blood plasma from patients with renal disease or atherosclerosis, and are present in atherosclerotic plaques. Chem. Res. Toxicol., 2000, Vol. 13, no. 7, pp. 557-564.

32. Schiopu A., Frendéus B., Jansson B., Söderberg I., Ljungcrantz I., Araya Z., Shah P.K., Carlsson R., Nilsson J., Fredrikson G.N. Recombinant antibodies to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in apobec-1(-/-)/low-density lipoprotein receptor(-/-) mice. J. Am. Coll. Cardiol., 2007, Vol. 50, no. 24, pp. 2313-2318.

33. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., Fujimoto E.K., Goeke N.M., Olson B.J., Klenk D.C. Measurement of protein using bicinchoninic acid. Anal. Biochem., 1985, Vol. 150, no. 1, pp. 76-85.

34. Tsimikas S., Brilakis E.S., Lennon R.J., Miller E.R., Witztum J.L., McConnell J.P., Kornman K.S., Berger P.B. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J. Lipid Res., 2007, Vol. 48, no. 2, pp. 425-433.

35. Turk Z., Skrabolo Z. The cell interactive properties of glucosylated very-low-density lipoproteins. Cell. Mol. Biol., 1987, Vol. 33, no. 3, pp. 345-354.

36. Wolf D., Ley K. Immunity and inflammation in atherosclerosis. Circ Res., 2019, Vol. 124, no. 2, pp. 315-327.

37. Yokoi M., Ito T., Fujita H., Sugiura T., Seo Y., Ohte N. Increased serum malondialdehyde-modified lowdensity lipoprotein and coronary angiographic progression after drug-eluting stent implantation in patients with stable angina. Circ. J., 2020, Vol. 84, no. 10, pp. 1837-1845.

38. Yokoi M., Ito T., Kawada Y., Mizoguchi T., Yamamoto J., Mori K., Nakasuka K., Kikuchi S., Fujita H., Kitada S., Goto T., Seo Y. Malondialdehyde-modified low-density lipoprotein as a predictor of major adverse limb events after endovascular therapy in patients with lower extremity arterial disease. J. Atheroscler. Thromb., 2023, Vol. 30, no. 11, pp. 1612-1621.

39. Zhang H.F., Basra H.J., Steinbrecher U.P. Effects of oxidatively modified LDL on cholesterol esterification in cultured macrophages. J. Lipid Res., 1990, Vol. 31, no. 8, pp. 1361-1369.